Thymosin alpha 1 for use in treatment of cystic fibrosis
Patent Number 12083165 - September 10, 2024
The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and…
Treatment of cancer with alpha thymosin peptide and PD-1 inhibitors
Patent Number 11571465 - February 7, 2023
The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the…
Thymosin alpha 1 for use in treatment of cystic fibrosis
Patent Number 11524056 - December 13, 2022
The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and…
Thymosin alpha 1 for use in treatment of cystic fibrosis
Patent Number 10478474 - November 19, 2019
The present invention concerns Thymosin alpha 1 for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and…
Treatment of cancer with immune stimulators
Patent Number 9724395 - August 8, 2017
The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the…
TREATMENT OF ASPERGILLUS INFECTIONS WITH ALPHA THYMOSIN PEPTIDES
Application Number 20120295840 - November 22, 2012
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The…
PREVENTION OR DELAY OF ONSET OF ORAL MUCOSITIS
Application Number 20110245316 - October 6, 2011
The present invention provides a method for preventing or delaying the onset of oral mucositis, including the onset of ulcerative or severe…
Treatment or Prevention of Hepatitis C with Immunomodulator Compounds
Application Number 20110200558 - August 18, 2011
A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an…
Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa
Application Number 20110117211 - May 19, 2011
An immunomodulatory compound is utilized to treat mucosa disease.
TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4)
Application Number 20100330093 - December 30, 2010
Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating…
Salpeter-Levy v. SciClone Pharmaceuticals, Inc. et al
California Northern District Court - August 29, 2017
Sciabacucchi v. SciClone Pharmaceuticals, Inc. et al
California Northern District Court - August 17, 2017
Consoli v. SciClone Pharmaceuticals, Inc. et al
California Northern District Court - August 16, 2017
Daley v. SciClone Pharmaceuticals, Inc. et al
California Northern District Court - August 9, 2017
Karner et al v. SciClone Pharmaceuticals, Inc. et al
California Northern District Court - September 7, 2010
"In re SciClone Pharmaceuticals Securities Litigation"
California Northern District Court - December 1, 2010
STIPULATION AND ORDER Granting Dismissal without Prejudice Pursuant to FRCP 41(a)(1) re 29 Stipulation. Signed by Judge James Ware on…
